At the 8mg dose, participants lost an average of 21.6kg of fat mass compared to placebo
While LBM loss appears to be less pronounced than FBM loss in many studies, the clinical significance of even modest reductions in skeletal muscle remains uncertain, particularly in older adults or individuals at risk of sarcopenia
This consistent interval directly influences the retatrutide timing post tirzepatide research cycle
Take them in the same lighting, same clothing, and same poses for meaningful comparison
Additionally, the improved insulin sensitivity and glucose regulation contribute to better metabolic function and reduced fat accumulation
When accompanied by metabolic disorders, such as IR and dyslipidaemia, it can lead to hyperlipidaemia, hypertension, metabolic syndrome and diabetes